Pomerantz Law Firm Investigates Valneva SE for Potential Securities Fraud
Pomerantz LLP is investigating Valneva SE (NASDAQ: VALN) for potential securities fraud following the announcement that its Lyme disease vaccine failed to meet its primary endpoint. Valneva's ADR price dropped by 37.11% after the news. The investigation focuses on whether the company and its officers engaged in unlawful business practices.
Topics: class action clinical trial failure Pfizer securities fraud stock price drop Valneva